JP2019525944A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525944A5
JP2019525944A5 JP2019505410A JP2019505410A JP2019525944A5 JP 2019525944 A5 JP2019525944 A5 JP 2019525944A5 JP 2019505410 A JP2019505410 A JP 2019505410A JP 2019505410 A JP2019505410 A JP 2019505410A JP 2019525944 A5 JP2019525944 A5 JP 2019525944A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
ruminococcus
bacterium
live non
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019505410A
Other languages
Japanese (ja)
Other versions
JP2019525944A (en
Filing date
Publication date
Priority claimed from US15/360,703 external-priority patent/US20180036352A1/en
Application filed filed Critical
Publication of JP2019525944A publication Critical patent/JP2019525944A/en
Publication of JP2019525944A5 publication Critical patent/JP2019525944A5/ja
Priority to JP2022186548A priority Critical patent/JP2023010890A/en
Pending legal-status Critical Current

Links

Claims (31)

治療を必要とする対象の潰瘍性大腸炎（ＵＣ）を治療するための、クロストリジウム（Ｃｌｏｓｔｒｉｄｉｕｍ）およびルミノコッカス（Ｒｕｍｉｎｏｃｏｃｃｕｓ）を含む生きた非病原性糞便細菌を含む薬学的組成物であって、A pharmaceutical composition comprising live non-pathogenic fecal bacteria, including Clostridium and Ruminococcus, for treating ulcerative colitis (UC) in a subject in need of treatment.
前記薬学的組成物が、１週間当たり少なくとも２回の、少なくとも１週間の治療レジメンに従って対象に経口的または経直腸的に投与され、ならびに、The pharmaceutical composition is orally or transrectally administered to the subject at least twice per week according to a treatment regimen for at least one week, and
前記糞便細菌が、消化管疾患の病歴または現症状を有しない１人または複数人のヒトドナーの糞便サンプルに由来する、薬学的組成物。A pharmaceutical composition in which the fecal bacterium is derived from a fecal sample of one or more human donors having no history or present symptoms of gastrointestinal disease. 治療レジメンが、薬学的組成物を経口投与することを含む、請求項１に記載の薬学的組成物。The pharmaceutical composition according to claim 1, wherein the therapeutic regimen comprises orally administering the pharmaceutical composition. 治療レジメンが、薬学的組成物を少なくとも２週間投与することを含む、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the therapeutic regimen comprises administering the pharmaceutical composition for at least 2 weeks. 治療レジメンが、薬学的組成物を１週間当たり少なくとも３回投与することを含む、請求項３に記載の薬学的組成物。The pharmaceutical composition according to claim 3, wherein the therapeutic regimen comprises administering the pharmaceutical composition at least three times per week. 生きた非病原性糞便細菌が、さらに、ブラウチア（Ｂｌａｕｔｉａ）、ドレア（Ｄｏｒｅａ）、または、その両方を含む、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium further comprises Blautia, Dorea, or both. 生きた非病原性糞便細菌が、さらに、ブラウチア（Ｂｌａｕｔｉａ）を含む、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium further comprises Blautia. 生きた非病原性糞便細菌が、さらに、ドレア（Ｄｏｒｅａ）を含む、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium further comprises Dorea. 生きた非病原性糞便細菌が、培養細菌を含む、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium comprises a cultured bacterium. 生きた非病原性糞便細菌が、生きた糞便細菌を含む、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium comprises a live fecal bacterium. 生きた非病原性糞便細菌が、胞子の形態にある、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium is in the form of spores. 生きた非病原性糞便細菌が、消化管疾患の病歴または現症状を有しない１人のドナーの糞便微生物叢を含む、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium comprises a fecal microflora of one donor having no history or present symptoms of gastrointestinal disease. 生きた非病原性糞便細菌が、消化管疾患の病歴または現症状を有しない複数のドナーに由来する、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, wherein the live non-pathogenic fecal bacterium is derived from a plurality of donors having no history or present symptoms of gastrointestinal disease. 対象の腸内における、フソバクテリウム（Ｆｕｓｏｂａｃｔｅｒｉｕｍ）、サテレラ（Ｓｕｔｔｅｒｅｌｌａ）、バルネシエラ（Ｂａｒｎｅｓｉｅｌｌａ）、パラバクテロイデス（Ｐａｒａｂａｃｔｅｒｏｉｄｅｓ）、クロストリジウムＩＶ（Ｃｌｏｓｔｒｉｄｉｕｍ ＩＶ）、ルミノコッカス（Ｒｕｍｉｎｏｃｏｃｃｕｓ）、ブラウチア（Ｂｌａｕｔｉａ）、ドレア（Ｄｏｒｅａ）、ルミノコッカス２（Ｒｕｍｉｎｏｃｏｃｃｕｓ２）、および、クロストリジウムＸＶＩＩＩ（Ｃｌｏｓｔｒｉｄｉｕｍ ＸＶＩＩＩ）からなる群から選択される１つまたは複数の細菌のレベルが決定された後、薬学的組成物が経口的または経直腸的に対象に投与される、請求項２に記載の薬学的組成物。In the subject's intestine, Fusobacterium, Sutterella, Barnesiella, Parabacteroides, Clostridium IV, Ruminococcus, Ruminococcus, Ruminococcus, Ruminococcus, Ruminococcus. After the level of one or more bacteria selected from the group consisting of Ruminococcus 2 and Clostridium XVIII has been determined, the pharmaceutical composition is orally or transrectally targeted. The pharmaceutical composition according to claim 2, which is administered. 治療を必要とする対象の潰瘍性大腸炎（ＵＣ）を治療するための、クロストリジウム（Ｃｌｏｓｔｒｉｄｉｕｍ）、ルミノコッカス（Ｒｕｍｉｎｏｃｏｃｃｕｓ）、ブラウチア（Ｂｌａｕｔｉａ）、および、ドレア（Ｄｏｒｅａ）からなる群から選択される少なくとも２つの属の生きた非病原性糞便細菌を含む、薬学的組成物であって、At least selected from the group consisting of Clostridium, Ruminococcus, Blautia, and Dorea for the treatment of ulcerative colitis (UC) in a subject in need of treatment. A pharmaceutical composition comprising two genera of live non-pathogenic fecal bacteria.
薬学的組成物が、１週間当たり少なくとも２回の少なくとも１週間の治療レジメンに従って、対象に経口的にまたは経直腸的に投与され、The pharmaceutical composition is administered to the subject orally or transrectally according to a treatment regimen of at least 2 times per week for at least 1 week.
前記対象は、コルチコステロイドの併用を前記方法実施中に行わず、The subject did not use corticosteroids in combination during the method.
前記対象は、方法を開始する前の少なくとも１週間以内のステロイド使用がなく、ならびに、The subject had no steroid use within at least one week prior to initiating the method, as well as
前記糞便細菌が、消化管疾患の病歴または現症状を有しない１人または複数人のヒトドナーの糞便サンプルに由来する、The fecal bacterium is derived from a fecal sample of one or more human donors who have no history or present symptoms of gastrointestinal disease.
薬学的組成物。Pharmaceutical composition. 治療レジメンが、薬学的組成物の経口投与を含む、請求項１４に記載の薬学的組成物。The pharmaceutical composition according to claim 14, wherein the therapeutic regimen comprises oral administration of the pharmaceutical composition. 治療レジメンが、薬学的組成物を少なくとも２週間投与することを含む、請求項１５に記載の薬学的組成物。15. The pharmaceutical composition of claim 15, wherein the therapeutic regimen comprises administering the pharmaceutical composition for at least 2 weeks. 治療レジメンが、薬学的組成物を１週間当たり少なくとも３回投与することを含む、請求項１６に記載の薬学的組成物。16. The pharmaceutical composition of claim 16, wherein the therapeutic regimen comprises administering the pharmaceutical composition at least three times per week. 生きた非病原性糞便細菌が、ブラウチア（Ｂｌａｕｔｉａ）、ドレア（Ｄｏｒｅａ）、または、その両方を含む、請求項１５に記載の薬学的組成物。15. The pharmaceutical composition of claim 15, wherein the live non-pathogenic fecal bacterium comprises Blautia, Dorea, or both. 生きた非病原性糞便細菌が、ブラウチア（Ｂｌａｕｔｉａ）を含む、請求項１５に記載の薬学的組成物。The pharmaceutical composition according to claim 15, wherein the live non-pathogenic fecal bacterium comprises Blautia. 生きた非病原性糞便細菌が、クロストリジウム（Ｃｌｏｓｔｒｉｄｉｕｍ）、ブラウチア（Ｂｌａｕｔｉａ）、および、ドレア（Ｄｏｒｅａ）を含む、請求項１５に記載の薬学的組成物。The pharmaceutical composition according to claim 15, wherein the live non-pathogenic fecal bacterium comprises Clostridium, Blautia, and Dorea. 生きた非病原性糞便細菌が、培養細菌を含む、請求項１５に記載の薬学的組成物。The pharmaceutical composition according to claim 15, wherein the live non-pathogenic fecal bacterium comprises a cultured bacterium. 生きた非病原性糞便細菌が、生きた糞便細菌を含む、請求項１５に記載の薬学的組成物。The pharmaceutical composition according to claim 15, wherein the live non-pathogenic fecal bacterium comprises a live fecal bacterium. 生きた非病原性糞便細菌が、胞子の形態にある、請求項１５に記載の薬学的組成物。The pharmaceutical composition according to claim 15, wherein the live non-pathogenic fecal bacterium is in the form of spores. 生きた非病原性糞便細菌が、消化管疾患の病歴または現症状を有しない１人のドナーの糞便微生物叢を含む、請求項１５に記載の薬学的組成物。15. The pharmaceutical composition of claim 15, wherein the live non-pathogenic fecal bacterium comprises a fecal microflora of one donor who has no history or present symptoms of gastrointestinal disease. 生きた非病原性糞便細菌が、消化管疾患の病歴または現症状を有しない複数のドナーに由来する、請求項１５に記載の薬学的組成物。15. The pharmaceutical composition of claim 15, wherein the live non-pathogenic fecal bacterium is derived from a plurality of donors having no history or present symptoms of gastrointestinal disease. 対象の腸内における、フソバクテリウム（Ｆｕｓｏｂａｃｔｅｒｉｕｍ）、サテレラ（Ｓｕｔｔｅｒｅｌｌａ）、バルネシエラ（Ｂａｒｎｅｓｉｅｌｌａ）、パラバクテロイデス（Ｐａｒａｂａｃｔｅｒｏｉｄｅｓ）、クロストリジウムＩＶ（Ｃｌｏｓｔｒｉｄｉｕｍ ＩＶ）、ルミノコッカス（Ｒｕｍｉｎｏｃｏｃｃｕｓ）、ブラウチア（Ｂｌａｕｔｉａ）、ドレア（Ｄｏｒｅａ）、ルミノコッカス２（Ｒｕｍｉｎｏｃｏｃｃｕｓ２）、および、クロストリジウムＸＶＩＩＩ（Ｃｌｏｓｔｒｉｄｉｕｍ ＸＶＩＩＩ）からなる群から選択される１つまたは複数の細菌のレベルが決定された後、薬学的組成物が経口的または経直腸的に対象に投与される、請求項１５に記載の薬学的組成物。In the subject's intestine, Fusobacterium, Sutterella, Barnesiella, Parabacteroides, Clostridium IV, Ruminococcus, Ruminococcus, Ruminococcus, Ruminococcus, Ruminococcus. After the level of one or more bacteria selected from the group consisting of Ruminococcus 2 and Clostridium XVIII has been determined, the pharmaceutical composition is orally or transrectally targeted. The pharmaceutical composition according to claim 15, which is administered. 生きた非病原性糞便細菌が、クロストリジウム（Ｃｌｏｓｔｒｉｄｉｕｍ）、ルミノコッカス（Ｒｕｍｉｎｏｃｏｃｃｕｓ）、ブラウチア（Ｂｌａｕｔｉａ）、および、ドレア（Ｄｏｒｅａ）を含む、請求項１５に記載の薬学的組成物。The pharmaceutical composition according to claim 15, wherein the live non-pathogenic fecal bacterium comprises Clostridium, Ruminococcus, Blautia, and Dorea. 少なくとも１週間毎日投与される、請求項１５に記載の薬学的組成物。The pharmaceutical composition according to claim 15, which is administered daily for at least one week. 少なくとも２週間毎日投与される、請求項１６に記載の薬学的組成物。The pharmaceutical composition according to claim 16, which is administered daily for at least 2 weeks. 少なくとも１週間毎日投与される、請求項２に記載の薬学的組成物。The pharmaceutical composition according to claim 2, which is administered daily for at least one week. 少なくとも２週間毎日投与される、請求項３に記載の薬学的組成物。The pharmaceutical composition according to claim 3, which is administered daily for at least 2 weeks.
JP2019505410A 2016-08-03 2017-08-02 Methods for treating ulcerative colitis Pending JP2019525944A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022186548A JP2023010890A (en) 2016-08-03 2022-11-22 Methods for treating ulcerative colitis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370508P 2016-08-03 2016-08-03
US62/370,508 2016-08-03
US15/360,703 US20180036352A1 (en) 2016-08-03 2016-11-23 Methods for treating ulcerative colitis
US15/360,703 2016-11-23
PCT/US2017/045092 WO2018026913A1 (en) 2016-08-03 2017-08-02 Methods for treating ulcerative colitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186548A Division JP2023010890A (en) 2016-08-03 2022-11-22 Methods for treating ulcerative colitis

Publications (2)

Publication Number Publication Date
JP2019525944A JP2019525944A (en) 2019-09-12
JP2019525944A5 true JP2019525944A5 (en) 2020-09-17

Family

ID=61071386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019505410A Pending JP2019525944A (en) 2016-08-03 2017-08-02 Methods for treating ulcerative colitis
JP2022186548A Pending JP2023010890A (en) 2016-08-03 2022-11-22 Methods for treating ulcerative colitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022186548A Pending JP2023010890A (en) 2016-08-03 2022-11-22 Methods for treating ulcerative colitis

Country Status (7)

Country Link
US (5) US20180036352A1 (en)
EP (1) EP3493822A1 (en)
JP (2) JP2019525944A (en)
CN (1) CN109803667A (en)
AU (1) AU2017306303A1 (en)
CA (1) CA3032004A1 (en)
WO (1) WO2018026913A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3045383B1 (en) 2015-12-18 2019-06-14 Maat Pharma PROCESS FOR THE FREEZING OF A FECAL MICROBIOTE SAMPLE
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
EP3664823B1 (en) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition for use in preventing or treating an enterococcal blood stream infection
KR102118203B1 (en) * 2018-03-06 2020-06-02 주식회사 엠디헬스케어 Nanovesicles derived from Coprococcus bacteria and Use thereof
FR3078627B1 (en) * 2018-03-09 2020-11-13 Maat Pharma PROCEDURE FOR COLLECTING STOOL AND PROCEDURE FOR PREPARING A SAMPLE FOR TRANSPLANTATION OF FECAL MICROBIOTE
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
CN109394795A (en) * 2018-10-23 2019-03-01 上海市第十人民医院 A kind of intestines bacterium capsule preparation method thereof and intestines bacterium capsule
JP2022517268A (en) * 2019-01-16 2022-03-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Methods and Compositions for Treating Immune Checkpoint Inhibitor-Related Colitis
US20230087012A1 (en) * 2020-02-14 2023-03-23 Cornell University Transferable microbiota for the treatment of ulcerative colitis
US11744866B2 (en) * 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
CN111888381A (en) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 Intestinal microorganism transplanting process
IL303884A (en) * 2020-12-23 2023-08-01 Maat Pharma France Sa A Conseil Dadministration Method of expanding a complex community of microorganisms
CN113509494A (en) * 2021-09-06 2021-10-19 南京医科大学 Application of prevotella in preparing medicine for treating cholestatic disease
CN114246886B (en) * 2021-12-24 2023-05-30 山西大学 Application of enterococcus faecalis in preparation for preventing and treating acute colitis

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (en) 1960-01-27 1961-11-30 Hoechst Ag Method for obtaining antitumor spores
FR1275M (en) 1961-05-06 1962-05-02 Rene Roger Medicinal product based on live colibacilli.
BE634858A (en) 1962-07-19 1900-01-01
FR2828M (en) 1963-03-01 1964-11-02 Lucien Nouvel Drug containing antibiotic-resistant colibacilli.
FR5528M (en) 1965-10-01 1967-11-13
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (en) 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (en) 1971-07-09 1973-01-25 Rolf Dr Schuler Prepns contg several bifidobacterium species - for normalizing intestinal flora
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (en) 1978-12-05 1983-07-29 Nestle Sa MICROBALL COMPRISING A MICROORGANISM AND ITS MANUFACTURING METHOD.
US4309782A (en) 1980-09-11 1982-01-12 Esteban Paulin Device for collecting fecal specimens
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4394377A (en) 1981-07-31 1983-07-19 Syntex (U.S.A.) Inc. Ruminant animal performance by co-administering choline and propionate enchancers
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
FI840816A0 (en) 1984-03-01 1984-03-01 Farmos Oy BAKTERIEPREPARAT
JPS615022A (en) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd Ameliorant of enterobacterial flora
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
CA1333564C (en) 1988-08-02 1994-12-20 Thomas Julius Borody Treatment of gastro-intestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
JP2961184B2 (en) 1990-05-07 1999-10-12 ミヤリサン株式会社 Pharmaceutical composition for prevention and treatment of Clostridium difficile diarrhea and pseudomembranous colitis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (en) 1992-04-24 2000-05-29 堀井薬品工業株式会社 Composition for intestinal lavage and intestinal lavage
JP3850891B2 (en) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 Composition having a laxative effect
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
JPH07242557A (en) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd Evacuant composition containing lactic acid bacterium
CA2191213C (en) 1994-05-26 2008-03-18 Lorenzo Morelli Lactobacillus strains of human origin, their compositions and uses thereof
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
AU1819897A (en) 1996-09-26 1998-04-17 Cuperman, Vladimir Borisovich Medicinal prophylactic "trisan"
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
WO1999057243A1 (en) 1998-05-06 1999-11-11 Keijiro Nakamura Microbial culture liquors containing microorganisms differing in characteristics and living in symbiosis and metabolites thereof, carriers and adsorbents containing the active components of the culture liquors and utilization of the same
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AT407008B (en) 1998-08-06 2000-11-27 Viernstein Helmut Dr FORMULATIONS WITH PROBIOTALLY EFFECTIVE MICROORGANISMS
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000015760A1 (en) 1998-09-17 2000-03-23 North American Vaccine, Inc. Streptococcal c beta protein compositions
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
PL348973A1 (en) 1998-12-11 2002-06-17 Urex Biotech Inc Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (en) 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
CN1183904C (en) 1999-02-26 2005-01-12 盐野义制药株式会社 Chewable soft capsules having improved administration properties and process for producing the same
FR2808689B1 (en) * 2000-05-11 2004-09-03 Agronomique Inst Nat Rech USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR THE PREVENTION OR TREATMENT OF DIGESTIVE DISORDERS
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
EP1303285A2 (en) 2000-07-17 2003-04-23 Chr. Hansen A/S Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
JP4756823B2 (en) 2001-06-01 2011-08-24 ポーゼン インコーポレイテッド Pharmaceutical composition for coordinated delivery of NSAIDs
US7846475B2 (en) 2001-07-05 2010-12-07 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
DE60325567D1 (en) 2002-04-05 2009-02-12 Euro Celtique Sa MATRIX FOR THE MODIFIED RELEASE OF ACTIVE SUBSTANCES
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
WO2005017095A2 (en) 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
US8168171B2 (en) 2004-08-05 2012-05-01 Probiotical S.P.A. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
ATE367821T1 (en) 2004-08-05 2007-08-15 Anidral Srl FOLIC ACID PRODUCING BIFIDOBACTERIUM BACTERIA STRAINS, THEIR FORMULATIONS AND USE
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
CN101217945B (en) 2005-05-20 2012-07-11 陶氏环球技术有限责任公司 Oral drug compliance monitoring using radio frequency identification tags
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
JP5006567B2 (en) 2006-04-14 2012-08-22 花王株式会社 Oral solid formulation
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (en) 2006-09-25 2008-05-08 Tashiro Yasuaki Composition containing saponin and viable bacterium
DE102006062250A1 (en) 2006-12-22 2008-06-26 Roland Saur-Brosch Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort
NZ579330A (en) 2007-03-01 2012-02-24 Probi Ab Use of lactobacillus plantarum for increasing bacterial diversity
MY146595A (en) 2007-03-28 2012-08-30 Alimentary Health Ltd Probiotic bifidobacterium strains
CA2682242A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium longum strain
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20100184785A1 (en) 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
EP2164462B1 (en) 2007-06-06 2017-05-31 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
JP5547068B2 (en) 2007-07-27 2014-07-09 カーギル インコーポレイテッド Micronization of polyols
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2009032560A1 (en) 2007-08-31 2009-03-12 Invista Technologies S.Ar.L. Oxygen scavenging plastic compositions
WO2009041651A1 (en) 2007-09-27 2009-04-02 Mitsubishi Tanabe Pharma Corporation Rapidly disintegrating solid preparation
EP2572705B1 (en) 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
US20100222311A1 (en) 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds
JP5327984B2 (en) 2007-10-20 2013-10-30 ユニベルシテ・ド・リエージュ Bifidobacterium species
CN101903032A (en) 2007-10-26 2010-12-01 布伦达·E.·穆尔 Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (en) 2007-11-19 2013-08-07 フロイント産業株式会社 Method for producing spherical particles
EP2233129B1 (en) 2007-12-28 2014-05-07 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
CN102245615A (en) 2008-10-02 2011-11-16 萨利克斯药品有限公司 Methods of treating hepatic encephalopathy
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (en) 2009-03-10 2010-09-16 Hero España, S.A. Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
ES2425385T3 (en) 2009-04-30 2013-10-15 Actogenix N.V. Cryoprotectants for lyophilization of lactic acid bacteria
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
CN201441672U (en) 2009-07-14 2010-04-28 赵伟华 Disposable enema device
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
CA2788558C (en) 2010-02-01 2015-11-24 Mikrobex, Inc. Bacteriotherapy for clostridium difficile colitis
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
BR112012022775A2 (en) 2010-03-10 2016-07-19 Nogra Pharma Ltd colon cleansing compositions and methods for producing and using them
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (en) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition having activity of inducing proliferation or accumulation of regulatory t cell
MX344831B (en) 2010-08-04 2017-01-04 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them.
AU2011313763A1 (en) 2010-10-04 2013-05-30 Emma Allen-Vercoe Detection of Fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
EP2624863B1 (en) 2010-10-07 2016-04-20 California Institute of Technology Probiotic therapies for autism
WO2012122478A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
CA2848757C (en) 2011-09-14 2021-11-09 University Of Guelph Methods to culture human gastrointestinal microorganisms
ES2582284T3 (en) 2011-10-11 2016-09-12 Achim Biotherapeutics Ab Composition comprising anaerobically cultured human intestinal microbiota
EP2785828B1 (en) 2011-12-01 2020-04-08 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US9176026B2 (en) 2011-12-15 2015-11-03 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
CN104662425B (en) 2012-05-02 2017-10-10 查尔斯河实验室公司 Vital staining method
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN104768560A (en) 2012-08-29 2015-07-08 加州理工学院 Diagnosis and treatment of autism spectrum disorder
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US20150297642A1 (en) 2012-11-26 2015-10-22 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
AU2014212004B2 (en) 2013-02-04 2018-09-20 Seres Therapeutics, Inc. Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
EP2968187A4 (en) 2013-03-14 2016-08-17 Therabiome Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN105307654B (en) 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 Compositions and methods for treating microbiota-related psychiatric conditions and diseases
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
DK3003330T3 (en) * 2013-06-05 2018-08-20 Rebiotix Inc Microbiota Recovery Treatment (MRI), compositions and methods of preparation
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9764019B2 (en) 2013-07-09 2017-09-19 Vedanta Biosciences, Inc. Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
AU2014331610B2 (en) 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
KR102379658B1 (en) 2013-11-25 2022-03-28 세레스 테라퓨틱스, 인코포레이티드 Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN114159476A (en) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 Compositions for fecal flora transplantation and methods for making and using them and devices for delivering them
WO2016191356A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
AU2016344049A1 (en) 2015-10-26 2018-05-10 Crestovo Holdings Llc Compositions and methods for fecal microbiota-related therapy
CN115919906A (en) 2016-03-04 2023-04-07 加利福尼亚大学董事会 Microbial consortia and uses thereof
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis

Similar Documents

Publication Publication Date Title
JP2019525944A5 (en)
JP2019520340A5 (en)
Sood et al. The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis
HRP20190659T1 (en) Compositions comprising a bacterial strain of blautia hydrogenotrophica for use in the treatment or prevention of diarrhea or constipation
Dinleyici et al. Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea
WO2008085484A3 (en) Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
JP2016529309A5 (en)
Liu et al. Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
JP2020502281A5 (en)
RU2018103081A (en) WAYS OF TREATMENT OF COLITES
JP2016505050A5 (en)
JP2020513018A5 (en)
Manhart et al. O02. 3 Treatment outcomes for persistent Mycoplasma genitalium-associated NGU: evidence of moxifloxacin treatment failures
ITMI950378A1 (en) ASSOCIATIONS OF LACTIC FERMENTS AND SACCAROMYCE LYSATES, THEIR THERAPEUTIC USE AND COMPOSITIONS THAT CONTAIN THEM
Kruis Probiotics
JP2019529572A5 (en)
JP7118594B2 (en) antidiarrheal composition
JP2014509656A5 (en)
EA201692107A1 (en) TREATMENT SCHEME TYACUMICINE CONNECTION
RU2007100833A (en) METHOD FOR TREATING INFECTIOUS FACILITY OF THE FACIAL NERVE IN THE ACUTE PERIOD
JP2013525440A5 (en)
RU2022116692A (en) METHOD FOR TREATMENT OF PEDIATRIC DISORDERS/DISEASES
Khosropour et al. O02. 4 Persistent/Recurrent Chlamydial Infection Among STD Clinic Patients Treated with CDC-Recommended Therapies
LIU et al. Anti-fatigue effects of N-benzylhexadecanamide and Maca extract in mice